Table 2 Comorbidity and medication at baseline.

From: Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Variable

Number of patients (%)

P-value *

Sitagliptin (n = 77)

Control (n = 71)

Comorbidity

Retinopathy

7 (9.1)

0 (0.0)

0.01

Nephropathy

25 (32.5)

17 (23.9)

0.28

Neuropathy

4 (5.2)

4 (5.6)

1.00

CAD

11 (14.3)

9 (12.7)

0.81

Stroke

7 (9.1)

5 (7.0)

0.77

Hypertension

46 (59.7)

41 (57.7)

0.87

Dyslipidemia

51 (66.2)

47 (66.2)

1.00

Liver disease

10 (13.0)

6 (8.5)

0.43

Kidney disease

17 (22.1)

11 (15.5)

0.40

Other diseases

28 (36.4)

28 (39.4)

0.74

Medication

Antidiabetics

53 (68.8)

60 (84.5)

0.03

Sulfonylureas

27 (35.1)

37 (52.1)

0.046

Metformin

36 (46.8)

33 (46.5)

1.00

Pioglitazone

20 (26.0)

17 (23.9)

0.85

α-Glucosidases

12 (15.6)

20 (28.2)

0.07

Glinides

1 (1.3)

2 (2.8)

0.61

Othersa

2 (2.6)

1 (1.4)

1.00

Antihypertensives

43 (55.8)

35 (49.3)

0.51

Lipid-lowering drug

43 (55.8)

37 (52.1)

0.74

Other drugs

34 (44.2)

37 (52.1)

0.41

  1. *Between-group differences based on Fisher’s exact test. CAD coronary artery disease. aEpalrestat prescribed for diabetic neuropathy (n = 1 in sitagliptin group and n = 1 in control group) and imidapril for diabetic nephropathy (n = 1 in sitagliptin group) are listed as others (other antidiabetic medications).
Back to article page